Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivonescimab + ipilimumab
- Development stage
- Phase 2
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ivonescimab + ipilimumab is an investigational combination immunotherapy regimen consisting of ivonescimab (SMT112/AK112), a novel bispecific antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), and ipilimumab (Yervoy), a recombinant human monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). This combination is designed to simultaneously block the PD-1/PD-L1 pathway, inhibit VEGF-mediated angiogenesis, and promote T-cell activation via CTLA-4 inhibition. The regimen is being evaluated in a Phase II clinical study (SMT112-216 / AK112-216 / NCT07877194) for the first-line treatment of patients with advanced clear cell renal cell carcinoma (ccRCC).
- Other names
- AK112 + ipilimumabSMT112 + ipilimumabivonescimab + Yervoyivonescimab plus ipilimumab
02
Targets
CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on ivonescimab + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivonescimab + ipilimumab.